Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 314


Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Kryst J, Kawalec P, Pilc A.

PLoS One. 2015 May 1;10(5):e0124279. doi: 10.1371/journal.pone.0124279. eCollection 2015.


Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.

Tittle V, Bull L, Boffito M, Nwokolo N.

Clin Pharmacokinet. 2015 Jan;54(1):23-34. doi: 10.1007/s40262-014-0204-8.


Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.

Lindsey JC, Hughes MD, Violari A, Eshleman SH, Abrams EJ, Bwakura-Dangarembizi M, Barlow-Mosha L, Kamthunzi P, Sambo PM, Cotton MF, Moultrie H, Khadse S, Schimana W, Bobat R, Zimmer B, Petzold E, Mofenson LM, Jean-Philippe P, Palumbo P; P1060 Study Team.

Pediatr Infect Dis J. 2014 Aug;33(8):846-54. doi: 10.1097/INF.0000000000000337.


First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.

Clumeck N, Mwamba C, Kabeya K, Matanda S, Vaira D, Necsoi C, Kadiebwe D, Delforge M, Kasamba E, Milolo C, Ilunga J, Kapend L.

AIDS. 2014 May 15;28(8):1143-53. doi: 10.1097/QAD.0000000000000214.


French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.

Hoen B, Bonnet F, Delaugerre C, Delobel P, Goujard C, L'Hénaff M, Persiaux R, Rey D, Rouzioux C, Taburet AM, Morlat P; 2013 French HIV expert group.

J Int AIDS Soc. 2014 Jun 17;17:19034. doi: 10.7448/IAS.17.1.19034. eCollection 2014.


Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.

Asmelash A, Zheng Y, Kaloustian KW, Shaffer D, Sawe F, Ogwu A, Salata R, Currier J, Hughes MD, Lockman S.

BMC Infect Dis. 2014 Jun 17;14:331. doi: 10.1186/1471-2334-14-331.


Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;5:CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.


Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).

Shaffer D, Hughes MD, Sawe F, Bao Y, Moses A, Hogg E, Lockman S, Currier J.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):155-63. doi: 10.1097/QAI.0000000000000131.


Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.

Slyker JA, Casper C, Tapia K, Richardson B, Bunts L, Huang ML, Wamalwa D, Benki-Nugent S, John-Stewart G.

Clin Infect Dis. 2014 May;58(9):1333-7. doi: 10.1093/cid/ciu088. Epub 2014 Feb 18.


Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.

Shiau S, Kuhn L, Strehlau R, Martens L, McIlleron H, Meredith S, Wiesner L, Coovadia A, Abrams EJ, Arpadi SM.

BMC Pediatr. 2014 Feb 12;14:39. doi: 10.1186/1471-2431-14-39.


Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.

Shiau S, Kuhn L.

Expert Rev Anti Infect Ther. 2014 Mar;12(3):307-18. doi: 10.1586/14787210.2014.888311. Epub 2014 Feb 9. Review.


Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.

Mwafongo A, Nkanaunena K, Zheng Y, Hogg E, Samaneka W, Mulenga L, Siika A, Currier J, Lockman S, Hughes MD, Hosseinipour M; AIDS Clinical Trial Group (ACTG) A5208 Team.

AIDS. 2014 May 15;28(8):1135-42. doi: 10.1097/QAD.0000000000000202.


Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies.

Perry SH, Swamy P, Preidis GA, Mwanyumba A, Motsa N, Sarero HN.

AIDS. 2014 Mar 13;28(5):791-3. doi: 10.1097/QAD.0000000000000177.


Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV-infected patients.

Abgrall S, Le Bel J, Lele N, Laouénan C, Eychenne N, Mentré F, Peytavin G, Bouchaud O; Vihvo Study Group.

HIV Clin Trials. 2013 Nov-Dec;14(6):313-8. doi: 10.1310/hct1406-313.


HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana.

Shapiro RL, Kitch D, Ogwu A, Hughes MD, Lockman S, Powis K, Souda S, Moffat C, Moyo S, McIntosh K, van Widenfelt E, Zwerski S, Mazhani L, Makhema J, Essex M.

AIDS. 2013 Jul 31;27(12):1911-20.


Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals.

Kiang TK, Wilby KJ, Ensom MH.

Clin Pharmacokinet. 2014 Feb;53(2):141-53. doi: 10.1007/s40262-013-0110-5. Review.


Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Reliquet V, Chirouze C, Allavena C, Muret P, Peytavin G, André-Garnier E, Bettinger D, Ferré V, Hoen B, Raffi F.

Antivir Ther. 2014;19(1):117-23. doi: 10.3851/IMP2691. Epub 2013 Oct 22.


Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.

Kawalec P, Kryst J, Mikrut A, Pilc A.

PLoS One. 2013 Oct 7;8(10):e76587. doi: 10.1371/journal.pone.0076587. eCollection 2013. Review.


Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.

Hashiguchi Y, Hamada A, Shinohara T, Tsuchiya K, Jono H, Saito H.

Biochem Biophys Res Commun. 2013 Sep 20;439(2):221-7. doi: 10.1016/j.bbrc.2013.08.054. Epub 2013 Aug 24.


Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.

Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, Guèye NF, Le Moing V, Eymard-Duvernay S, Benalycherif A, Charpentier C, Peytavin G, Delaporte E, Girard PM; DAYANA Study Group.

Antivir Ther. 2014;19(1):51-9. doi: 10.3851/IMP2675. Epub 2013 Aug 23.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk